Literature DB >> 21281430

Effect of mutant β-catenin on liver growth homeostasis and hepatocarcinogenesis in transgenic mice.

Timothy J Stein1, Adam Jochem, Katie E Holmes, Eric P Sandgren.   

Abstract

BACKGROUND: Mutations in the Wnt signalling pathway molecule β-catenin are associated with liver cancer. AIMS: Our aim was to confirm the effects of stabilized β-catenin on liver growth, identify whether those effects were reversible and cell autonomous or non-cell autonomous and to model β-catenin-induced liver cancer in mice.
METHODS: Using a liver-specific inducible promoter, we generated transgenic mice in which the expression of mutant β-catenin can be induced or repressed within hepatocytes in mice of different ages.
RESULTS: Similar to other models, the hepatic expression of mutant β-catenin in our model beginning in utero or induced in quiescent adult liver resulted in a two-fold liver enlargement and development of disease with a latency of 1-5 months, and mice displayed elevated blood ammonia and altered hepatic gene expression. Our model additionally allowed us to discover that molecular and phenotypic abnormalities were reversible following the inhibition of transgene expression. Hepatocyte transplant studies indicated that mutant β-catenin could not increase the growth of transgene-expressing foci in either growth-permissive or -restrictive hepatic environments, but still directly altered hepatocyte gene expression. Mice with continuous but focal transgene expression developed hepatic neoplasms after the age of 1 year.
CONCLUSIONS: Our findings indicate that hepatocyte gene expression is directly affected by mutant β-catenin in a cell autonomous manner. However, hepatomegaly associated with diffuse hepatocyte-specific expression of mutant β-catenin is secondary to liver functional alteration or non-cell autonomous. Both phenotypes are reversible. Nevertheless, some foci of transgene-expressing cells progressed to carcinoma, confirming the association of mutant β-catenin with liver cancer.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21281430      PMCID: PMC3093768          DOI: 10.1111/j.1478-3231.2010.02430.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  31 in total

1.  Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection.

Authors:  H Huang; H Fujii; A Sankila; B M Mahler-Araujo; M Matsuda; G Cathomas; H Ohgaki
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors.

Authors:  H Aydinlik; T D Nguyen; O Moennikes; A Buchmann; M Schwarz
Journal:  Oncogene       Date:  2001-11-22       Impact factor: 9.867

3.  Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin.

Authors:  A Cadoret; C Ovejero; S Saadi-Kheddouci; E Souil; M Fabre; B Romagnolo; A Kahn; C Perret
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

4.  Hepatocyte transplantation into diseased mouse liver. Kinetics of parenchymal repopulation and identification of the proliferative capacity of tetraploid and octaploid hepatocytes.

Authors:  T C Weglarz; J L Degen; E P Sandgren
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

5.  Quantifying growth and transformation frequency of oncogene-expressing mouse hepatocytes in vivo.

Authors:  Marxa L Figueiredo; Kristin M Wentworth; Eric P Sandgren
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

6.  Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis.

Authors:  H C Hsu; Y M Jeng; T L Mao; J S Chu; P L Lai; S Y Peng
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

7.  Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin.

Authors:  Naomoto Harada; Hiroyuki Miyoshi; Naomi Murai; Hiroko Oshima; Yoshitaka Tamai; Masanobu Oshima; Makoto M Taketo
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

8.  Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade.

Authors:  D F Calvisi; V M Factor; R Loi; S S Thorgeirsson
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

9.  Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.

Authors:  Ken Taniguchi; Lewis R Roberts; Ileana N Aderca; Xiangyang Dong; Chiping Qian; Linda M Murphy; David M Nagorney; Lawrence J Burgart; Patrick C Roche; David I Smith; Julie A Ross; Wanguo Liu
Journal:  Oncogene       Date:  2002-07-18       Impact factor: 9.867

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  2 in total

1.  c-Myc and transforming growth factor α enhance the development of hepatic lesions due to mutant β-catenin in transgenic mice.

Authors:  Adam S Jochem; Katie E Holmes; Timothy J Stein
Journal:  Comp Med       Date:  2014-10       Impact factor: 0.982

2.  Mutant Hras(G12V) and Kras(G12D) have overlapping, but non-identical effects on hepatocyte growth and transformation frequency in transgenic mice.

Authors:  Marxa L Figueiredo; Timothy J Stein; Adam Jochem; Eric P Sandgren
Journal:  Liver Int       Date:  2012-01-03       Impact factor: 5.828

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.